NCT01571999View on ClinicalTrials.gov

Study to Assess the Safety and PK of GSK573719 and GSK573719/GW642444(VI) Combination in Healthy Subjects and Subjects With Severe Renal Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

March 29, 2012

Primary Completion Date

June 22, 2012

Study Completion Date

June 22, 2012

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

Inhaled GSK573719

All subjects will receive a single dose of GSK573719 (125mcg) in treatment period 1

DRUG

Inhaled GSK573719/vilanterol

All subjects will receive a single dose of GSK573719 (125mcg)/vilanterol (25mcg) in treatment period 2

Trial Locations (2)

170 00

GSK Investigational Site, Prague

H-1076

GSK Investigational Site, Budapest

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01571999 - Study to Assess the Safety and PK of GSK573719 and GSK573719/GW642444(VI) Combination in Healthy Subjects and Subjects With Severe Renal Impairment | Biotech Hunter | Biotech Hunter